Damage control: Harnessing prostaglandin E2 as a potential healing factor of tissue injuries
| Autor: | Hue H. Luu, Emily Lu, Aravind Athiviraham, Christine Shen, Tong-Chuan He, Rex C. Haydon, Connie Shao, Michael J Lee |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
medicine.medical_treatment
Prostaglandin E2 Disease Biochemistry Article 03 medical and health sciences 0302 clinical medicine medicine Colitis Molecular Biology Genetics (clinical) 030304 developmental biology Cancer 0303 health sciences Chemotherapy business.industry Hematopoietic stem cell Cell Biology medicine.disease Tissue injury 3. Good health COX activity Haematopoiesis medicine.anatomical_structure 030220 oncology & carcinogenesis Immunology Cancer research Tissue regeneration lipids (amino acids peptides and proteins) Stem cell business medicine.drug |
| Zdroj: | Genes & Diseases. 2(4):295-298 |
| ISSN: | 2352-3042 |
| DOI: | 10.1016/j.gendis.2015.09.002 |
| Popis: | Increasing prostaglandin E2 by knocking out its inhibitor 15-hydroxyprostaglandin dehydrogenase (15-PDGH) or administering a compound that inhibits 15-PDGH was recently found to improve healing in hematopoietic stem cell transplants, colitis recovery, and hepatogenesis after transection in mice. These results are suggestive of pharmacologic therapies or even genetic therapy that could improve patient outcomes, especially since the excess PGE2 and the 15-PDGH inhibitor have proven to be non-toxic. However, elevated levels of PGE2 are associated with increased risk of cancer and blood clotting problems. It would be unacceptable to treat a cancer patient with chemotherapy and replenish the hematopoietic stem cells with the help of PGE2, only to have increased expression of PGE2 and induce another cancer. Therefore, to assess the most therapeutic aspects of PGE2, it is important to consider effects that could induce disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|